SpyGlass Pharma Inc (SGP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$28.94-0.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SGP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on enrolling patients in two registrational Phase 3 trials of the BIM-IOL System, aiming to complete enrollment in 2027.
Stated as a priority in 2 of last 2 quarters. Management reiterated that enrollment in the Phase 3 BIM-IOL System trials remains on track for completion in 2027. No revenue data is available yet, but the consistent focus on enrollment progress indicates delivering on this clinical development milestone.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Enrollment remains on track in the registrational Phase 3 trials of the BIM-IOL System, with completion expected in 2027.”
“Enrollment remains on track in the registrational Phase 3 trials of the BIM-IOL System, with completion of enrollment expected in 2027.”
Start the first-in-human clinical trial of the Bimatoprost-Drug Ring System (BIM-DRS) in the second half of 2026 to expand treatment options.
Stated as a priority in 2 of last 2 quarters. Management consistently targets initiation of the BIM-DRS first-in-human trial in the second half of 2026. This clinical milestone is on track with no revenue yet, reflecting steady progress in pipeline expansion.
“Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.”
“Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.”
Maintain sufficient cash, cash equivalents, and short-term investments to fund planned operations through 2028.
Stated as a priority in 3 of last 3 quarters. Cash and short-term investments decreased slightly from $251.0 million in 2026-Q1 to $234.2 million in 2026-Q2 but remain sufficient to fund planned operations through 2028 as management has consistently stated. The trajectory is delivering on maintaining a strong cash runway.
“Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, expected to fund planned operations through 2028.”
“Cash, cash equivalents and short-term investments of $251.0 million on March 31, 2026, expected to fund planned operations through 2028.”
“With the IPO proceeds, SpyGlass Pharma expects its current cash position to fund planned operations through 2028.”
Prepare for commercial launch of BIM-IOL System by securing reimbursement codes and strengthening commercial leadership and surgeon engagement.
Newly stated in 2026-Q2. Management highlighted securing a dedicated reimbursement pathway via a new CPT code and strengthening commercial leadership with a new VP Marketing appointment to support BIM-IOL System commercialization. This is an early-stage commercial readiness priority with no revenue yet.
“American Medical Association approved new add-on Category III CPT code for BIM-IOL System reimbursement; appointed VP Marketing.”
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.